SCM
ADPT icon

Soleus Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Soleus Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$117K – 90
2025
Q2 		$117K Hold
10,000
– – 0.01% 95
2025
Q1 		$74.3K Sell
10,000
-2,973,142
-100% -$22.9M 0.01% 75
2024
Q4 		$17.9M Buy
2,983,142
+1,870,393
+168% +$10.3M 1.12% 28
2024
Q3 		$5.7M Sell
1,112,749
-607,251
-35% -$2.65M 0.44% 56
2024
Q2 		$6.23M Buy
+1,720,000
New +$5.46M 0.55% 56

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Soleus Capital Management's ADPT Position: Q3 2025 in Review

Soleus Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2025, closing a stake of 10,000 shares — an estimated $117K sold.

Soleus Capital Management first reported a position in ADPT in Q2 2024 and held it in 5 quarters. The position peaked at $17.9M in Q4 2024. 271 funds tracked by Wall St. Rank hold ADPT as of Q3 2025.

  • Soleus Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2025 after selling out during the quarter.
  • Soleus Capital Management sold 10,000 Adaptive Biotechnologies shares in Q3 2025, an estimated $117K.
  • Soleus Capital Management first reported a position in Adaptive Biotechnologies in Q2 2024 and held it in 5 quarters.
  • Soleus Capital Management's Adaptive Biotechnologies position peaked at $17.9M in Q4 2024.
  • 271 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.